Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 80

1.

Defining a correlate of protection for chikungunya virus vaccines.

Milligan GN, Schnierle BS, McAuley AJ, Beasley DWC.

Vaccine. 2018 Nov 15. pii: S0264-410X(18)31399-9. doi: 10.1016/j.vaccine.2018.10.033. [Epub ahead of print]

PMID:
30448337
2.

Current status of Severe Fever with Thrombocytopenia Syndrome vaccine development.

Reece LM, Beasley DW, Milligan GN, Sarathy VV, Barrett AD.

Curr Opin Virol. 2018 Apr;29:72-78. doi: 10.1016/j.coviro.2018.03.005. Epub 2018 Apr 9. Review.

PMID:
29642053
3.

Baseline mapping of Lassa fever virology, epidemiology and vaccine research and development.

Hallam HJ, Hallam S, Rodriguez SE, Barrett ADT, Beasley DWC, Chua A, Ksiazek TG, Milligan GN, Sathiyamoorthy V, Reece LM.

NPJ Vaccines. 2018 Mar 20;3:11. doi: 10.1038/s41541-018-0049-5. eCollection 2018. Review.

4.

Zika virus infection elicits auto-antibodies to C1q.

Koma T, Veljkovic V, Anderson DE, Wang LF, Rossi SL, Shan C, Shi PY, Beasley DW, Bukreyeva N, Smith JN, Hallam S, Huang C, von Messling V, Paessler S.

Sci Rep. 2018 Jan 30;8(1):1882. doi: 10.1038/s41598-018-20185-8.

5.

Cross-neutralisation of viruses of the tick-borne encephalitis complex following tick-borne encephalitis vaccination and/or infection.

McAuley AJ, Sawatsky B, Ksiazek T, Torres M, Korva M, Lotrič-Furlan S, Avšič-Županc T, von Messling V, Holbrook MR, Freiberg AN, Beasley DWC, Bente DA.

NPJ Vaccines. 2017 Mar 13;2:5. doi: 10.1038/s41541-017-0009-5. eCollection 2017.

6.

Supramolecular peptide hydrogel adjuvanted subunit vaccine elicits protective antibody responses against West Nile virus.

Friedrich BM, Beasley DWC, Rudra JS.

Vaccine. 2016 Nov 4;34(46):5479-5482. doi: 10.1016/j.vaccine.2016.09.044. Epub 2016 Sep 23.

PMID:
27670075
7.

First vaccine approval under the FDA Animal Rule.

Beasley DWC, Brasel TL, Comer JE.

NPJ Vaccines. 2016 Aug 25;1:16013. doi: 10.1038/npjvaccines.2016.13. eCollection 2016.

8.

Research and development of Zika virus vaccines.

Dawes BE, Smalley CA, Tiner BL, Beasley DW, Milligan GN, Reece LM, Hombach J, Barrett AD.

NPJ Vaccines. 2016 Jul 28;1:16007. doi: 10.1038/npjvaccines.2016.7. eCollection 2016.

9.

Plasticity of a critical antigenic determinant in the West Nile virus NY99 envelope protein domain III.

Plante JA, Torres M, Huang CY, Beasley DWC.

Virology. 2016 Sep;496:97-105. doi: 10.1016/j.virol.2016.05.024. Epub 2016 Jun 7.

10.

ELISA and Neutralization Methods to Measure Anti-West Nile Virus Antibody Responses.

Friedrich BM, Beasley DW.

Methods Mol Biol. 2016;1435:129-41. doi: 10.1007/978-1-4939-3670-0_11.

PMID:
27188555
11.

Propagation and Titration of West Nile Virus on Vero Cells.

McAuley AJ, Beasley DW.

Methods Mol Biol. 2016;1435:19-27. doi: 10.1007/978-1-4939-3670-0_3.

PMID:
27188547
12.

Status of research and development of vaccines for chikungunya.

Smalley C, Erasmus JH, Chesson CB, Beasley DWC.

Vaccine. 2016 Jun 3;34(26):2976-2981. doi: 10.1016/j.vaccine.2016.03.076. Epub 2016 Mar 26.

13.

Recovery of West Nile Virus Envelope Protein Domain III Chimeras with Altered Antigenicity and Mouse Virulence.

McAuley AJ, Torres M, Plante JA, Huang CY, Bente DA, Beasley DWC.

J Virol. 2016 Apr 14;90(9):4757-4770. doi: 10.1128/JVI.02861-15. Print 2016 May.

14.

Utilization of an Eilat Virus-Based Chimera for Serological Detection of Chikungunya Infection.

Erasmus JH, Needham J, Raychaudhuri S, Diamond MS, Beasley DW, Morkowski S, Salje H, Fernandez Salas I, Kim DY, Frolov I, Nasar F, Weaver SC.

PLoS Negl Trop Dis. 2015 Oct 22;9(10):e0004119. doi: 10.1371/journal.pntd.0004119. eCollection 2015.

15.

Immunogenicity and efficacy of flagellin-envelope fusion dengue vaccines in mice and monkeys.

Liu G, Song L, Beasley DW, Putnak R, Parent J, Misczak J, Li H, Reiserova L, Liu X, Tian H, Liu W, Labonte D, Duan L, Kim Y, Travalent L, Wigington D, Weaver B, Tussey L.

Clin Vaccine Immunol. 2015 May;22(5):516-25. doi: 10.1128/CVI.00770-14. Epub 2015 Mar 11.

16.

Yellow fever virus: genetic and phenotypic diversity and implications for detection, prevention and therapy.

Beasley DW, McAuley AJ, Bente DA.

Antiviral Res. 2015 Mar;115:48-70. doi: 10.1016/j.antiviral.2014.12.010. Epub 2014 Dec 26. Review.

PMID:
25545072
17.

Multiplexed digital mRNA profiling of the inflammatory response in the West Nile Swiss Webster mouse model.

Peña J, Plante JA, Carillo AC, Roberts KK, Smith JK, Juelich TL, Beasley DW, Freiberg AN, Labute MX, Naraghi-Arani P.

PLoS Negl Trop Dis. 2014 Oct 23;8(10):e3216. doi: 10.1371/journal.pntd.0003216. eCollection 2014 Oct.

18.

Enhancement of protein expression by alphavirus replicons by designing self-replicating subgenomic RNAs.

Kim DY, Atasheva S, McAuley AJ, Plante JA, Frolova EI, Beasley DW, Frolov I.

Proc Natl Acad Sci U S A. 2014 Jul 22;111(29):10708-13. doi: 10.1073/pnas.1408677111. Epub 2014 Jul 7.

19.

Thermodynamic mechanism for the evasion of antibody neutralization in flaviviruses.

Maillard RA, Liu T, Beasley DW, Barrett AD, Hilser VJ, Lee JC.

J Am Chem Soc. 2014 Jul 23;136(29):10315-24. doi: 10.1021/ja503318x. Epub 2014 Jul 8.

20.

GeneSV - an Approach to Help Characterize Possible Variations in Genomic and Protein Sequences.

Zemla A, Kostova T, Gorchakov R, Volkova E, Beasley DW, Cardosa J, Weaver SC, Vasilakis N, Naraghi-Arani P.

Bioinform Biol Insights. 2014 Jan 8;8:1-16. doi: 10.4137/BBI.S13076. eCollection 2014 Jan 8.

21.

Co-circulation of West Nile virus variants, Arizona, USA, 2010.

Plante JA, Burkhalter KL, Mann BR, Godsey MS Jr, Mutebi JP, Beasley DW.

Emerg Infect Dis. 2014 Feb;20(2):272-5. doi: 10.3201/eid2002.131008.

22.

Resurgence of West Nile neurologic disease in the United States in 2012: what happened? What needs to be done?

Beasley DW, Barrett AD, Tesh RB.

Antiviral Res. 2013 Jul;99(1):1-5. doi: 10.1016/j.antiviral.2013.04.015. Epub 2013 Apr 26.

PMID:
23624155
23.

Adaptation of yellow fever virus 17D to Vero cells is associated with mutations in structural and non-structural protein genes.

Beasley DW, Morin M, Lamb AR, Hayman E, Watts DM, Lee CK, Trent DW, Monath TP.

Virus Res. 2013 Sep;176(1-2):280-4. doi: 10.1016/j.virusres.2013.04.003. Epub 2013 Apr 16.

PMID:
23602827
24.

Molecular evolution of lineage 2 West Nile virus.

McMullen AR, Albayrak H, May FJ, Davis CT, Beasley DW, Barrett AD.

J Gen Virol. 2013 Feb;94(Pt 2):318-25. doi: 10.1099/vir.0.046888-0. Epub 2012 Nov 7.

25.

Mutational analysis of the West Nile virus NS4B protein.

Wicker JA, Whiteman MC, Beasley DW, Davis CT, McGee CE, Lee JC, Higgs S, Kinney RM, Huang CY, Barrett AD.

Virology. 2012 Apr 25;426(1):22-33. doi: 10.1016/j.virol.2011.11.022. Epub 2012 Feb 6.

26.

Conservation of the DENV-2 type-specific and DEN complex-reactive antigenic sites among DENV-2 genotypes.

Pitcher TJ, Gromowski GD, Beasley DW, Barrett AD.

Virology. 2012 Jan 20;422(2):386-92. doi: 10.1016/j.virol.2011.10.020. Epub 2011 Dec 5.

27.

Reduced avian virulence and viremia of West Nile virus isolates from Mexico and Texas.

Brault AC, Langevin SA, Ramey WN, Fang Y, Beasley DW, Barker CM, Sanders TA, Reisen WK, Barrett AD, Bowen RA.

Am J Trop Med Hyg. 2011 Oct;85(4):758-67. doi: 10.4269/ajtmh.2011.10-0439.

28.

Envelope and pre-membrane protein structural amino acid mutations mediate diminished avian growth and virulence of a Mexican West Nile virus isolate.

Langevin SA, Bowen RA, Ramey WN, Sanders TA, Maharaj PD, Fang Y, Cornelius J, Barker CM, Reisen WK, Beasley DW, Barrett AD, Kinney RM, Huang CY, Brault AC.

J Gen Virol. 2011 Dec;92(Pt 12):2810-20. doi: 10.1099/vir.0.035535-0. Epub 2011 Aug 24.

29.

Safety and immunogenicity of a chimeric vaccine for West Nile virus in aged subjects.

Beasley DW.

Expert Rev Vaccines. 2011 May;10(5):601-4. doi: 10.1586/erv.11.47.

PMID:
21604981
30.

Vaccines and immunotherapeutics for the prevention and treatment of infections with West Nile virus.

Beasley DW.

Immunotherapy. 2011 Feb;3(2):269-85. doi: 10.2217/imt.10.93. Review.

PMID:
21322763
31.

Direct complement restriction of flavivirus infection requires glycan recognition by mannose-binding lectin.

Fuchs A, Lin TY, Beasley DW, Stover CM, Schwaeble WJ, Pierson TC, Diamond MS.

Cell Host Microbe. 2010 Aug 19;8(2):186-95. doi: 10.1016/j.chom.2010.07.007.

32.

Role of BC loop residues in structure, function and antigenicity of the West Nile virus envelope protein receptor-binding domain III.

Zhang S, Bovshik EI, Maillard R, Gromowski GD, Volk DE, Schein CH, Huang CY, Gorenstein DG, Lee JC, Barrett AD, Beasley DW.

Virology. 2010 Jul 20;403(1):85-91. doi: 10.1016/j.virol.2010.03.038. Epub 2010 May 6.

33.

Inactivated yellow fever 17D vaccine: development and nonclinical safety, immunogenicity and protective activity.

Monath TP, Lee CK, Julander JG, Brown A, Beasley DW, Watts DM, Hayman E, Guertin P, Makowiecki J, Crowell J, Levesque P, Bowick GC, Morin M, Fowler E, Trent DW.

Vaccine. 2010 May 14;28(22):3827-40. doi: 10.1016/j.vaccine.2010.03.023. Epub 2010 Mar 26.

PMID:
20347059
34.

Persistent infection with West Nile virus years after initial infection.

Murray K, Walker C, Herrington E, Lewis JA, McCormick J, Beasley DW, Tesh RB, Fisher-Hoch S.

J Infect Dis. 2010 Jan 1;201(1):2-4. doi: 10.1086/648731.

35.

Development and characterization of non-glycosylated E and NS1 mutant viruses as a potential candidate vaccine for West Nile virus.

Whiteman MC, Li L, Wicker JA, Kinney RM, Huang C, Beasley DW, Chung KM, Diamond MS, Solomon T, Barrett AD.

Vaccine. 2010 Jan 22;28(4):1075-83. doi: 10.1016/j.vaccine.2009.10.112. Epub 2009 Nov 5.

PMID:
19896447
36.

Development pathway for biodefense vaccines.

Barrett AD, Beasley DW.

Vaccine. 2009 Nov 5;27 Suppl 4:D2-7. doi: 10.1016/j.vaccine.2009.07.094. Review.

PMID:
19837280
37.

Structure of yellow fever virus envelope protein domain III.

Volk DE, May FJ, Gandham SH, Anderson A, Von Lindern JJ, Beasley DW, Barrett AD, Gorenstein DG.

Virology. 2009 Nov 10;394(1):12-8. doi: 10.1016/j.virol.2009.09.001. Epub 2009 Oct 8.

38.

NMR assignments of the sylvatic dengue 1 virus envelope protein domain III.

Volk DE, Anderson KM, Gandham SH, May FJ, Li L, Beasley DW, Barrett AD, Gorenstein DG.

Biomol NMR Assign. 2008 Dec;2(2):155-7. doi: 10.1007/s12104-008-9109-5. Epub 2008 Aug 12.

39.

Development of resistance to passive therapy with a potently neutralizing humanized monoclonal antibody against West Nile virus.

Zhang S, Vogt MR, Oliphant T, Engle M, Bovshik EI, Diamond MS, Beasley DW.

J Infect Dis. 2009 Jul 15;200(2):202-5. doi: 10.1086/599794.

40.

Characterization of Culex Flavivirus (Flaviviridae) strains isolated from mosquitoes in the United States and Trinidad.

Kim DY, Guzman H, Bueno R Jr, Dennett JA, Auguste AJ, Carrington CV, Popov VL, Weaver SC, Beasley DW, Tesh RB.

Virology. 2009 Mar 30;386(1):154-9. doi: 10.1016/j.virol.2008.12.034. Epub 2009 Feb 3.

41.

Genetic variation of St. Louis encephalitis virus.

May FJ, Li L, Zhang S, Guzman H, Beasley DW, Tesh RB, Higgs S, Raj P, Bueno R Jr, Randle Y, Chandler L, Barrett AD.

J Gen Virol. 2008 Aug;89(Pt 8):1901-10. doi: 10.1099/vir.0.2008/000190-0.

42.

Current use and development of vaccines for Japanese encephalitis.

Beasley DW, Lewthwaite P, Solomon T.

Expert Opin Biol Ther. 2008 Jan;8(1):95-106. Review.

PMID:
18081539
43.

Long range communication in the envelope protein domain III and its effect on the resistance of West Nile virus to antibody-mediated neutralization.

Maillard RA, Jordan M, Beasley DW, Barrett AD, Lee JC.

J Biol Chem. 2008 Jan 4;283(1):613-22. Epub 2007 Nov 6.

44.

Solution structure of the envelope protein domain III of dengue-4 virus.

Volk DE, Lee YC, Li X, Thiviyanathan V, Gromowski GD, Li L, Lamb AR, Beasley DW, Barrett AD, Gorenstein DG.

Virology. 2007 Jul 20;364(1):147-54. Epub 2007 Mar 29.

45.

Thioaptamer decoy targeting of AP-1 proteins influences cytokine expression and the outcome of arenavirus infections.

Fennewald SM, Scott EP, Zhang L, Yang X, Aronson JF, Gorenstein DG, Luxon BA, Shope RE, Beasley DW, Barrett AD, Herzog NK.

J Gen Virol. 2007 Mar;88(Pt 3):981-90.

PMID:
17325372
46.

Selection of thioaptamers for diagnostics and therapeutics.

Yang X, Wang H, Beasley DW, Volk DE, Zhao X, Luxon BA, Lomas LO, Herzog NK, Aronson JF, Barrett AD, Leary JF, Gorenstein DG.

Ann N Y Acad Sci. 2006 Oct;1082:116-9.

PMID:
17145932
47.

A mutation in the envelope protein fusion loop attenuates mouse neuroinvasiveness of the NY99 strain of West Nile virus.

Zhang S, Li L, Woodson SE, Huang CY, Kinney RM, Barrett AD, Beasley DW.

Virology. 2006 Sep 15;353(1):35-40. Epub 2006 Jun 27.

48.

Structure of the envelope protein domain III of Omsk hemorrhagic fever virus.

Volk DE, Chavez L, Beasley DW, Barrett AD, Holbrook MR, Gorenstein DG.

Virology. 2006 Jul 20;351(1):188-95. Epub 2006 May 2.

49.

A single amino acid substitution in the central portion of the West Nile virus NS4B protein confers a highly attenuated phenotype in mice.

Wicker JA, Whiteman MC, Beasley DW, Davis CT, Zhang S, Schneider BS, Higgs S, Kinney RM, Barrett AD.

Virology. 2006 Jun 5;349(2):245-53. Epub 2006 Apr 19.

50.

Introductions of West Nile virus strains to Mexico.

Deardorff E, Estrada-Franco J, Brault AC, Navarro-Lopez R, Campomanes-Cortes A, Paz-Ramirez P, Solis-Hernandez M, Ramey WN, Davis CT, Beasley DW, Tesh RB, Barrett AD, Weaver SC.

Emerg Infect Dis. 2006 Feb;12(2):314-8.

Supplemental Content

Loading ...
Support Center